More recently, Kim et al. [165] developed nanocomplexes carrying siRNAs against MALAT-1 that efficiently enhanced sensitivity of glioblastoma tumor cells to temozolomide both in vitro and in vivo. Here, MALAT1 is linked to neoplasm.